Dirk Beher is the chief executive officer and a founder of Asceneuron SA with more than two decades of experience in CNS drug discovery in large biopharma and smaller biotechnology companies. During his time in the industry, Dr. Beher has contributed to the development of numerous clinical-stage drug candidates and provided mechanistic insights how these molecules exert their effects in preclinical disease models. His goal is to develop a disease-modifying drug for one of the major neurodegenerative diseases such as Alzheimer’s disease or Parkinson’s disease. Dr. Beher has authored more than 50 peer-reviewed scientific articles and reviews, as well as multiple patents.
Assessment of Alpha-synuclein Aggregation Inhibitor ASN121151 as a Potential New Treatment for Parkinson’s Disease